Osteonecrosis of the Femoral Head in Korean Patients with Human Immunodeficiency Virus Infection

Background Osteonecrosis of the femoral head (ONFH) is a disabling condition that often necessitates total hip arthroplasty (THA). Although ONFH occurs more frequently among patients with human immunodeficiency virus (HIV) than among the general population, there is little epidemiological information regarding ONFH in Korean patients with HIV. In the present study, we aimed to investigate the incidence and clinical features of ONFH among Korean patients with HIV. Materials and Methods In this retrospective study, we reviewed the medical records of 1,250 Korean patients with HIV treated from January 1990 to December 2019. A standardised data collection sheet was used to obtain clinical information. Imaging data were analysed by a radiologist in accordance with the 2019 revised version of the Association Research Circulation Osseous (ARCO) staging system for ONFH. Results Among the 1,250 included patients, 13 patients (1.04%; 3 women, 10 men) were diagnosed with ONFH. The overall incidence of ONFH was 1.29 per 1,000 person-years (PYs) (95% confidence interval [CI]: 0.7 – 2.4 per 1,000 PYs). Median age among the 13 patients with ONFH was 47 years (interquartile range [IQR]: 41 – 57 years). The median duration since HIV diagnosis was 4.8 years (IQR: 2.3 – 10.1 years). The median CD4 cell count at the time of ONFH diagnosis was 381 cells/ mm3 (IQR: 161 – 551 cells/mm3). At the initial diagnosis of ONFH, 83.3% of patients exhibited bilateral involvement. ARCO stage 3 or 4 osteonecrosis was observed in 83% of patients. Among 22 hips, stage 1 ONFH was noted in 2 (9.1%), stage 2 ONFH was noted in 7 (31.8%), stage 3 ONFH was noted in 9 (40.9%), and stage 4 ONFH was noted in 4 (18.2%). THA was eventually performed in 84.6% of patients. Five (38.5%) patients had a history of steroid use, 4 (30.8%) patients had a history of alcohol abuse and 10 (76.9%) were smokers. Eight (61.5%) patients had a history of acquired immune deficiency syndrome-defining illness, including 7 with tuberculosis and 1 with pneumocystis pneumonia. Nine patients (69.2%) had a nadir CD4 cell count <200/µL, and 3 (23.1%) had a history of bone fracture. Overall, 84% of patients were exposed to antiretroviral therapy, while 54% had taken protease inhibitors for more than 1 year. Conclusion Considering that relatively high incidence of ONFH in patients with HIV, a high index of suspicion for those with risk factors and those with groin or hip pain for is required in HIV-infected patients.

[1]  W. Maloney,et al.  Diagnosis of Osteonecrosis of the Femoral Head: Too Little, Too Late, and Independent of Etiology. , 2020, The Journal of arthroplasty.

[2]  J. Parvizi,et al.  The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head. , 2019, The Journal of arthroplasty.

[3]  C. Leen,et al.  Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  N. Wang,et al.  Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey , 2015, Chinese medical journal.

[5]  E. Cheng,et al.  Osteonecrosis of the femoral head: diagnosis and classification systems , 2015, Current Reviews in Musculoskeletal Medicine.

[6]  E. Knight,et al.  Protease inhibitors and avascular necrosis: a systematic review and meta-analysis. , 2014, International journal of antimicrobial agents.

[7]  N. Kim,et al.  Avascular Necrosis of Femoral Head in HIV-infected Patients: Case Reports and Review of the Literature , 2012 .

[8]  Sohee Park,et al.  Prevalence of osteonecrosis of the femoral head: a nationwide epidemiologic analysis in Korea. , 2009, The Journal of arthroplasty.

[9]  J. Yombi,et al.  Osteonecrosis of the femoral head in patients with type 1 human immunodeficiency virus infection: clinical analysis and review , 2009, Clinical Rheumatology.

[10]  Hsin-Yun Sun,et al.  Osteonecrosis in patients with human immunodeficiency virus type 1 infection in Taiwan. , 2007, Japanese journal of infectious diseases.

[11]  J. Kovacs,et al.  The incidence and natural history of osteonecrosis in HIV-infected adults. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  D. Costagliola,et al.  Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy , 2006, AIDS.

[13]  J. Flores,et al.  Osteonecrosis in Patients Infected With HIV: Clinical Epidemiology and Natural History in a Large Case Series From Spain , 2006, Journal of acquired immune deficiency syndromes.

[14]  H. Günthard,et al.  Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. , 2004, AIDS research and human retroviruses.

[15]  R. Davey,et al.  High Prevalence of Osteonecrosis of the Femoral Head in HIV-Infected Adults , 2002, Annals of Internal Medicine.

[16]  Richard D Moore,et al.  Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic , 2002, AIDS.

[17]  R. Chaisson,et al.  Increasing incidence of avascular necrosis of the hip in HIV-infected patients. , 2001, Journal of acquired immune deficiency syndromes.

[18]  D. Hoover,et al.  Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study. , 2001, The Journal of infectious diseases.

[19]  D. Skiest,et al.  Osteonecrosis in HIV: A Case‐Control Study , 2000, Journal of acquired immune deficiency syndromes.

[20]  W. Peh.  Avascular necrosis of the hip. , 2000, American journal of orthopedics.

[21]  M. Newman.  Bone disorders, hypertension, and mitochondrial toxicity in HIV disease. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.